

David J. Pinskey et al.  
U.S. Serial No.:09/053,871  
Filed: April 1, 1998  
Page 2

--DETOXI-GEL™--

21 Factor IX

The method of claim 29,  
wherein the patient  
has experienced an  
ischemic event



In the claims:

Please amend claim 29 as follows:

21  
A  
--29. (amended) A method of inhibiting clot formation in a subject which comprises adding to blood an amount of an inactive recombinant mutein in an amount effective to inhibit clot formation in the subject but which does not significantly interfere with hemostasis when the blood is administered to a patient.

wherein the inactive recombinant mutein comprises:

(a) a proteolytically inactive recombinant mutein of Factor IX, or  
(b) a proteolytically inactive recombinant mutein of Factor IXa

and wherein the recombinant mutein comprises a substitution, deletion, or addition of one or more amino acids to wild-type Factor IX or wild-type Factor IXa resulting in reduced ability to convert Factor X to Factor Xa.

11/17/01  
Markush

22  
--33. (new) The method of claim 29, wherein the recombinant mutein of Factor IX comprises an amino acid substitution for one or more of His221, Asp269 or Ser365 of wild-type Factor IX.

23  
--34. (new) The method of claim 33, wherein the substitution for Ser365 of wild-type Factor IX is alanine.